Premium
Ipsapirone in the treatment of bulimia nervosa: An open pilot study
Author(s) -
Geretsegger Christian,
Greimel Karoline V.,
Roed Llona S.,
Hesselink Jan M. Keppel
Publication year - 1995
Publication title -
international journal of eating disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.785
H-Index - 138
eISSN - 1098-108X
pISSN - 0276-3478
DOI - 10.1002/1098-108x(199505)17:4<359::aid-eat2260170407>3.0.co;2-c
Subject(s) - ipsapirone , bulimia nervosa , binge eating , open label , agonist , psychology , partial agonist , psychiatry , eating disorders , medicine , randomized controlled trial , receptor , buspirone
Seventeen women who met the criteria for bulimia nervosa (DSM‐III‐R) were treated for 4 weeks in an open trial with ipsapirone, a partial 5‐HT 1A agonist. Bulimic symptoms diminished in 66.6% of the patients after only 1 week of treatment, 93.3% showed a reduction of more than 50% of weekly binge eating attacks after 4 weeks. The mean frequency of binges was reduced by 81% at endpoint. Ipsapirone was well tolerated. © 1995 by John Wiley & Sons, Inc.